Cuorips Inc.
Research Cuorips Inc. (4894.T) on Bullrun: market cap JPY 55.67B. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- Ticker4894.T
- ExchangeTSE
- CountryJapan
- SectorHealthcare
- IndustryBiotechnology
- CurrencyJPY
- Market capJPY 55.67B
- Financial periodFY2026
- RevenueJPY 212.33M
- Revenue growth21.2%
- Net income-JPY 1.02B
- Free cash flow-JPY 1.11B
- Gross margin61.4%
Valuation Snapshot
latest market cap is JPY 55.67B.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2026 | JPY 212.33M | -JPY 1.02B | -JPY 1.11B | 61.4% | -124.54 | JPY 3.65B | n/a | JPY 4.75B |
| FY2025 | JPY 175.21M | -JPY 644.34M | -JPY 902.47M | 96.0% | -80.52 | JPY 4.59B | n/a | JPY 5.53B |
| FY2024 | JPY 23.10M | -JPY 632.18M | -JPY 487.01M | 41.7% | -85.86 | JPY 5.56B | n/a | JPY 5.98B |
| FY2023 | JPY 38.28M | -JPY 452.08M | -JPY 412.18M | 54.9% | -59.94 | JPY 2.94B | n/a | JPY 3.45B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-18 | JPY 55.67B | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 JPY.
About Cuorips Inc.
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets in Japan. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Osaka, Japan.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Cuorips Inc.'s market cap?
Cuorips Inc.'s market capitalization is JPY 55.67B.
What does Cuorips Inc. do?
Cuorips Inc. engages in the research, development, manufacture, commercialization, and sale of human iPS cell-derived cardiomyocyte sheets in Japan. The company offers cellular and tissue-based, and cell processing products. It also provides contract development and manufacturing, and consulting services. The company was formerly known as Cuore Inc. and changed its name to Cuorips Inc. in June 2017. Cuorips Inc. was incorporated in 2017 and is headquartered in Osaka, Japan.